Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone marrow transplant

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    432 result(s) found for: Bone marrow transplant. Displaying page 22 of 22.
    «« First « Previous 14  15  16  17  18  19  20  21  22 
    EudraCT Number: 2019-003333-42 Sponsor Protocol Number: EZH-302 Start Date*: 2020-11-09
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refr...
    Medical condition: Relapsed/refractory follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.0 10016903 - Follicle centre lymphomas, follicular grade I, II, III 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001795-38 Sponsor Protocol Number: ALLTogether1 Start Date*: 2020-05-15
    Sponsor Name:Karolinska University Hospital
    Full Title: ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)
    Medical condition: Acute lymphoblastic leukaemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) NO (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004699-16 Sponsor Protocol Number: KRT-232-117 Start Date*: 2021-03-15
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukem...
    Medical condition: Phase 1b and Phase 2 Arms A and B: Adults with tumor protein 53 wild type (TP53wt) Philadelphia chromosome positive (Ph+) CML in chronic phase who are refractory or intolerant to ≥ 2 prior TKIs and...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10009015 Chronic myeloid leukemia LLT
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    22.0 100000004864 10082178 Philadelphia positive chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004599-19 Sponsor Protocol Number: INTERFANT-06 Start Date*: 2005-11-24
    Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR INFANTS UNDER ONE YEAR WITH ACUTE LYMPHOBLASTIC OR BIPHENOTYPIC LEUKEMIA
    Medical condition: acute lymphoblastic leukemia (ALL) or biphenotypic leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) FR (Ongoing) DE (Completed) GB (Completed) AT (Ongoing) PT (Completed) DK (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004535-30 Sponsor Protocol Number: MK-0457 Start Date*: 2007-03-22
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
    Medical condition: CML and Ph+ALL
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) PT (Completed) DE (Prematurely Ended) FR (Completed) NL (Completed) DK (Prematurely Ended) GB (Completed) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000066-11 Sponsor Protocol Number: 114-022 Start Date*: 2018-09-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoie...
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013778-41 Sponsor Protocol Number: C18770/2043 Start Date*: 2011-08-29
    Sponsor Name:Cephalon, Inc.
    Full Title: An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy.
    Medical condition: Patients with relapsed multiple myeloma refractory to the most recent therapy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    14.1 10005329 - Blood and lymphatic system disorders 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005197-10 Sponsor Protocol Number: VT3996-202 Start Date*: 2021-10-01
    Sponsor Name:Viracta Therapeutics, Inc.
    Full Title: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
    Medical condition: Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071441 Epstein-Barr virus associated lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003526-80 Sponsor Protocol Number: CLSG-PTCL-CHEPA Start Date*: 2021-12-16
    Sponsor Name:Kooperativní lymfomová skupina, z.s.
    Full Title: A Phase II Open Label Study of Brentuximab Vedotin in combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas.
    Medical condition: Peripheral T-cell lymphomas (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002450 Angioimmunoblastic T-cell lymphomas HLT
    20.0 100000004851 10001414 Adult T-cell lymphomas/leukaemias HLT
    20.0 100000004851 10022704 Intestinal T-cell lymphomas HLT
    20.0 100000004851 10034622 Peripheral T-cell lymphomas NEC HLT
    21.0 100000004864 10002451 Angioimmunoblastic T-cell lymphoma NOS LLT
    21.0 100000004864 10001415 Adult T-cell lymphoma/leukaemia NOS LLT
    21.1 100000004864 10076434 Hepatosplenic gamma-delta T-cell lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003171-39 Sponsor Protocol Number: T-Control Start Date*: 2016-03-08
    Sponsor Name:University Hospital Wuerzburg
    Full Title: Transfer of Streptamer-selected multi-antigen specific T cells to prevent infections and relapse and to reduce the risk of Graft-versus-Host Disease after allogeneic stem cell transplantation
    Medical condition: patients with hematological malignancies after T cell depleted allo-SCT
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000845 Acute lymphoblastic leukemia LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000846 Acute lymphocytic leukaemia PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028576 Myeloproliferative disorder PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025311 Lymphoma (non-Hodgkin's) LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028534 Myelodysplastic syndrome NOS LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10013238 Disorder myeloproliferative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004813-26 Sponsor Protocol Number: GCP#04.01.020/030 Start Date*: 2016-03-14
    Sponsor Name:Gamida Cell Ltd
    Full Title: Long Term Follow Up for Patients who have received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
    Medical condition: High risk haematological malignancies Hemoglobinopathies
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10025316 Lymphoma NOS LLT
    18.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    18.1 100000004864 10000886 Acute myeloid leukemia LLT
    18.1 100000004850 10054658 Thalassemia LLT
    18.1 100000004864 10009015 Chronic myeloid leukemia LLT
    18.1 100000004850 10040645 Sickle cell disease NOS LLT
    18.1 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001073-86 Sponsor Protocol Number: MT-3724_NHL_001 Start Date*: 2020-01-14
    Sponsor Name:Molecular Templates, Inc.
    Full Title: Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory DLBCL
    Medical condition: relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 14  15  16  17  18  19  20  21  22 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 10:29:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA